You are here
Dehydroepiandrosterone Combination Receives FDA Orphan Drug Status
The FDA’s orphan drug program is intended to encourage research, development and approval of products for diseases that affect fewer than 200,000 patients in the United States. Orphan drug designation will provide Fidelin™ with seven years of market exclusivity following regulatory approval.
Paladin acquired the development and marketing rights to DHEA in 1999 through its acquisition of Neuroscience Pharma Inc., a company focused on the discovery and development of novel therapeutics relating to DHEA. Paladin is continuing the development of this product for adrenal insufficiency, a rare chronic condition brought about by failure of the adrenal glands, which affects an estimated 100,000 patients in the U.S. Current standard therapies frequently fail to restore full well being, and as such, patients with this disorder continue to suffer from a diminished quality of life.
"The FDA’s decision follows in close succession to our recent orphan drug designation for Fidelin™ in Europe,” said Dr. Tom Koutsavlis, MD, MSc, Vice President of Scientific Affairs at Paladin. “The combination of orphan drug designations for Fidelin™ in both Europe and the United States supports our continued investment in developing this novel and effective therapy for adrenal insufficiency."
Source: Paladin Labs Inc.